Search research articles
Contact Us
Filters
Showing results (121-130 of 230) with videos related to
Page
of 23
Sort By:
European Child & Adolescent Psychiatry
|
December 12, 2007
Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis
Edmund J S Sonuga-Barke, Pol Van Lier, James M Swanson, et al.
The Australian and New Zealand Journal of Psychiatry
|
August 24, 2022
Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: A population-based study among Australian children and adults (2013-2020)
Claudia Bruno, Alys Havard, Malcolm B Gillies, et al.
European Child & Adolescent Psychiatry
|
December 21, 2006
Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment
Anne W Riley, Georg Spiel, David Coghill, et al.
Autism : the International Journal of Research and Practice
|
January 4, 2023
Quality and accessibility of written development assessment reports provided to caregivers in a publicly funded child developmental assessment service
Martha Munro, Kelsie A Boulton, Natalie Phillips, et al.
The Lancet. Psychiatry
|
November 8, 2018
Unbalanced risk-benefit analysis of ADHD drugs - Authors' reply
Andrea Cipriani, Nicoletta Adamo, Cinzia Del Giovane, et al.
Journal of Comparative Effectiveness Research
|
November 24, 2018
Validity and reliability of the Dundee difficult times of the day scale in Chinese children and adolescents with attention-deficit/hyperactivity disorder
Yasong Du, Yi Zheng, Xiaoyan Ke, et al.
European Child & Adolescent Psychiatry
|
August 28, 2024
Reply: the inclusion of methylphenidate in the WHO list of essential medicines is endorsed by millions of people with ADHD
Samuele Cortese, David Coghill, Joerg M Fegert, et al.
European Child & Adolescent Psychiatry
|
April 25, 2024
ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines
Samuele Cortese, David Coghill, Joerg M Fegert, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines
|
January 9, 2013
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents
Samuele Cortese, Martin Holtmann, Tobias Banaschewski, et al.
Journal of Psychiatric Research
|
October 7, 2025
Emotional dysregulation, executive functions and callous-unemotional traits in children and adolescents with Oppositional Defiant Disorder/Conduct Disorder and Autism Spectrum Disorder: a direct comparison
Chiara Narducci, Federica Donno, Annarita Milone, et al.
Page
of 23
Search research articles
Search
Showing results (121-130 of 230) with videos related to
Sort By:
Page
of 23
European Child & Adolescent Psychiatry
|
December 12, 2007
Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis
Edmund J S Sonuga-Barke, Pol Van Lier, James M Swanson, et al.
The Australian and New Zealand Journal of Psychiatry
|
August 24, 2022
Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: A population-based study among Australian children and adults (2013-2020)
Claudia Bruno, Alys Havard, Malcolm B Gillies, et al.
European Child & Adolescent Psychiatry
|
December 21, 2006
Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment
Anne W Riley, Georg Spiel, David Coghill, et al.
Autism : the International Journal of Research and Practice
|
January 4, 2023
Quality and accessibility of written development assessment reports provided to caregivers in a publicly funded child developmental assessment service
Martha Munro, Kelsie A Boulton, Natalie Phillips, et al.
The Lancet. Psychiatry
|
November 8, 2018
Unbalanced risk-benefit analysis of ADHD drugs - Authors' reply
Andrea Cipriani, Nicoletta Adamo, Cinzia Del Giovane, et al.
Journal of Comparative Effectiveness Research
|
November 24, 2018
Validity and reliability of the Dundee difficult times of the day scale in Chinese children and adolescents with attention-deficit/hyperactivity disorder
Yasong Du, Yi Zheng, Xiaoyan Ke, et al.
European Child & Adolescent Psychiatry
|
August 28, 2024
Reply: the inclusion of methylphenidate in the WHO list of essential medicines is endorsed by millions of people with ADHD
Samuele Cortese, David Coghill, Joerg M Fegert, et al.
European Child & Adolescent Psychiatry
|
April 25, 2024
ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines
Samuele Cortese, David Coghill, Joerg M Fegert, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines
|
January 9, 2013
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents
Samuele Cortese, Martin Holtmann, Tobias Banaschewski, et al.
Journal of Psychiatric Research
|
October 7, 2025
Emotional dysregulation, executive functions and callous-unemotional traits in children and adolescents with Oppositional Defiant Disorder/Conduct Disorder and Autism Spectrum Disorder: a direct comparison
Chiara Narducci, Federica Donno, Annarita Milone, et al.
Page
of 23